Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS

Current Computer-Aided Drug Design

Volumn 6, Issue 1, 2010, Pages 1-23

  Shah, Falgun ^a   Mukherjee, Prasenjit ^a,b   Desai, Prashant ^a,c   Avery, Mitchell ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cysteine protease; Falcipain; Knowledge based drug design; Malaria; SARS

Indexed keywords

AMINO ACIDS; DISEASES; KNOWLEDGE BASED SYSTEMS; LIFE CYCLE; LIGANDS;

COMPUTATIONAL APPROACH; CYSTEINE PROTEASE; CYSTEINE PROTEASE INHIBITORS; DESIGN APPROACHES; DRUG DESIGN; FALCIPAIN; KNOWLEDGE BASED; KNOWLEDGE-BASED DRUG DESIGN; MALARIA; PHYSIOLOGICAL PROCESS;

SARS;

CYSTEINE PROTEINASE INHIBITOR;

DRUG DESIGN; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRTUAL REALITY; ANIMAL; BIOLOGY; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; PROCEDURES;

ANIMALS; COMPUTATIONAL BIOLOGY; CYSTEINE PROTEINASE INHIBITORS; DRUG DISCOVERY; HUMANS; MALARIA; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 77950522452     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340910790980142     Document Type: Review

References (170)

1. Lecaille, F.; Kaleta, J.; Bromme, D. Human and parasitic papainlike cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev., 2002, 102, 4459-4488.
2. Powers, J.C.; Asgian, J.L.; Ekici, O.D.; James, K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev., 2002, 102, 4639-4750.
3. Barrett, A.J.; Rawlings, N.D. Evolutionary lines of cysteine peptidases. Biol. Chem., 2001, 382, 727-733.
4. Leung-Toung, R.; Zhao, Y.; Li, W.; Tam, T.F.; Karimian, K.; Spino, M. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem., 2006, 13, 547-581.
5. Tong, L. Viral proteases. Chem. Rev., 2002, 102, 4609-4626.
6. Rota, P.A.; Oberste, M.S.; Monroe, S.S.; Nix, W.A.; Campagnoli, R.; Icenogle, J.P.; Penaranda, S.; Bankamp, B.; Maher, K.; Chen, M.H.; Tong, S.; Tamin, A.; Lowe, L.; Frace, M.; DeRisi, J.L.; Chen, Q.; Wang, D.; Erdman, D.D.; Peret, T.C.; Burns, C.; Ksiazek, T.G.; Rollin, P.E.; Sanchez, A.; Liffick, S.; Holloway, B.; Limor, J.; McCaustland, K.; Olsen-Rasmussen, M.; Fouchier, R.; Gunther, S.; Osterhaus, A.D.; Drosten, C.; Pallansch, M.A.; Anderson, L.J.; Bellini, W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003, 300, 1394-1399. (Pubitemid 36638152)
7. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J.R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (Washington, DC, U. S.), 2003, 300,1763-1767. (Pubitemid 36712575)
8. Dragovich, P.S.; Prins, T.J.; Zhou, R.; Johnson, T.O.; Hua, Y.; Luu, H.T.; Sakata, S.K.; Brown, E.L.; Maldonado, F.C.; Tuntland, T.; Lee, C.A.; Fuhrman, S.A.; Zalman, L.S.; Patick, A.K.; Matthews, D.A.; Wu, E.Y.; Guo, M.; Borer, B.C.; Nayyar, N.K.; Moran, T.; Chen, L.; Rejto, P.A.; Rose, P.W.; Guzman, M.C.; Dovalsantos, E.Z.; Lee, S.; McGee, K.; Mohajeri, M.; Liese, A.; Tao, J.; Kosa, M.B.; Liu, B.; Batugo, M.R.; Gleeson, J.P.; Wu, Z.P.; Liu, J.; Meador, J.W., 3rd; Ferre, R.A. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J. Med. Chem., 2003, 46, 4572-4585.
9. Huang, L.; Brinen, L.S.; Ellman, J.A. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem., 2003, 11, 21-29.
10. Marquis, R.W.; Ru, Y.; Zeng, J.; Trout, R.E.; LoCastro, S.M.; Gribble, A.D.; Witherington, J.; Fenwick, A.E.; Garnier, B.; Tomaszek, T.; Tew, D.; Hemling, M.E.; Quinn, C.J.; Smith, W.W.; Zhao, B.; McQueney, M.S.; Janson, C.A.; D'Alessio, K.; Veber, D.F. Cyclic ketone inhibitors of the cysteine protease cathepsin K. J. Med. Chem., 2001, 44, 725-736. (Pubitemid 32171669)
11. Batra, S.; Sabnis, Y.A.; Rosenthal, P.J.; Avery, M.A. Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-Trisubstituted dihydroisoquinolines and isoquinolines. Bioorg. Med. Chem., 2003, 11, 2293-2299.
12. Sabnis, Y.; Rosenthal, P.J.; Desai, P.; Avery, M.A. Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J. Biomol. Struct. Dyn., 2002, 19, 765-774.
13. Dragovich, P.S.; Webber, S.E.; Babine, R.E.; Fuhrman, S.A.; Patick, A.K.; Matthews, D.A.; Lee, C.A.; Reich, S.H.; Prins, T.J.; Marakovits, J.T.; Littlefield, E.S.; Zhou, R.; Tikhe, J.; Ford, C.E.; Wallace, M.B.; Meador, J.W., 3rd; Ferre, R.A.; Brown, E.L.; Binford, S.L.; Harr, J.E.; DeLisle, D.M.; Worland, S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem., 1998, 41, 2806-2818.
14. Ettari, R.; Nizi, E.; Di Francesco, M.E.; Dude, M.A.; Pradel, G.; Vicik, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappala, M. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. J. Med. Chem., 2008, 51, 988-996.
15. Donkor, I.O. A survey of calpain inhibitors. Curr. Med. Chem., 2000, 7, 1171-1188.
16. Zhu, S.; Hudson, T.H.; Kyle, D.E.; Lin, A.J. Synthesis and in vitro studies of novel pyrimidinyl peptidomimetics as potential antimalarial therapeutic agents. J. Med. Chem., 2002, 45, 3491-3496.
17. Chen, L.; Chen, S.; Gui, C.; Shen, J.; Shen, X.; Jiang, H. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays. J. Biomol. Screen., 2006, 11, 915-921.
18. Mukherjee, P.; Desai, P.; Ross, L.; White, E.L.; Avery, M.A. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits. Bioorg. Med. Chem., 2008, 16,4138-4149.
19. World Malaria Report 2008, http://malaria.who.int/wmr2008/ [Access date: August 8, 2009].
20. Katzung, B.G. Basic and Clinical Pharmacology, 8th ed.; Lange Medical Books/McGraw-Hill: New York, 2001.
21. Klemba, M.; Goldberg, D.E. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem., 2002, 71, 275-305.
22. Rosenthal, P.J. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol., 2002, 9, 140-145.
23. Brady, R.L.; Cameron, A. Structure-based approaches to the development of novel anti-malarials. Curr. Drug Targets, 2004, 5,137-149. (Pubitemid 38279412)
24. Sajid, M.; McKerrow, J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol., 2002, 120, 1-21.
25. Shenai, B.R.; Sijwali, P.S.; Singh, A.; Rosenthal, P.J. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem., 2000, 275, 29000-29010.
26. Dahl, E.L.; Rosenthal, P.J. Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. Mol. Biochem. Parasitol., 2005, 139, 205-212. (Pubitemid 40128216)
27. Sijwali, P.S.; Shenai, B.R.; Gut, J.; Singh, A.; Rosenthal, P.J. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J., 2001, 360, 481-489. (Pubitemid 33151343)
28. Sijwali, P.S.; Koo, J.; Singh, N.; Rosenthal, P.J. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol. Biochem. Parasitol., 2006, 150, 96-106.
29. Rosenthal, P.J.; Sijwali, P.S.; Singh, A.; Shenai, B.R. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des., 2002, 8, 1659-1672. (Pubitemid 34752832)
30. Greenbaum, D.C.; Baruch, A.; Grainger, M.; Bozdech, Z.; Medzihradszky, K.F.; Engel, J.; DeRisi, J.; Holder, A.A.; Bogyo, M. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science, 2002, 298, 2002-2006. (Pubitemid 35425258)
31. Sijwali, P.S.; Rosenthal, P.J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 2004, 101, 4384-4389.
32. Hanspal, M.; Dua, M.; Takakuwa, Y.; Chishti, A.H.; Mizuno, A. Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. Blood, 2002, 100, 1048-1054.
33. Sabnis, Y.A.; Desai, P.V.; Rosenthal, P.J.; Avery, M.A. Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies. Protein Sci., 2003, 12, 501-509.
34. Joachimiak, M.P.; Chang, C.; Rosenthal, P.J.; Cohen, F.E. The impact of whole genome sequence data on drug discovery - a malaria case study. Mol. Med., 2001, 7, 698-710.
35. Goh, L.L.; Sim, T.S. Homology modeling and mutagenesis analyses of Plasmodium falciparum falcipain 2A: implications for rational drug design. Biochem. Biophys. Res. Commun., 2004, 323,565-572.
36. Hogg, T.; Nagarajan, K.; Herzberg, S.; Chen, L.; Shen, X.; Jiang, H.; Wecke, M.; Blohmke, C.; Hilgenfeld, R.; Schmidt, C.L. Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J. Biol. Chem., 2006, 281, 25425-25437.
37. Kerr, I.D.; Lee, J.H.; Pandey, K.C.; Harrison, A.; Sajid, M.; Rosenthal, P.J.; Brinen, L.S. Structures of falcipain-2 and falcipain- 3 bound to small molecule inhibitors: implications for substrate specificity. J. Med. Chem., 2009, 52, 852-857.
38. Wang, S.X.; Pandey, K.C.; Scharfstein, J.; Whisstock, J.; Huang, R.K.; Jacobelli, J.; Fletterick, R.J.; Rosenthal, P.J.; Abrahamson, M.; Brinen, L.S.; Rossi, A.; Sali, A.; McKerrow, J.H. The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family. Structure, 2007,15, 535-543. (Pubitemid 46705555)
39. Wang, S.X.; Pendey, K.C.; Somoza, J.R.; Sijwali, P.S.; Kortemme, T.; Brinen, L.S.; Fletterick, R.J.; Rosenthal, P.J.; McKerrow, J.H. Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc. Natl. Acad. Sci. USA, 2006, 103, 11503-11508.
40. Singh, N.; Sijwali, P.S.; Pandey, K.C.; Rosenthal, P.J. Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2'. Exp. Parasitol., 2006, 112, 187-192. (Pubitemid 43247780)
41. Hanzlik, R.P.; Jacober, S.P.; Zygmunt, J. Reversible binding of peptide aldehydes to papain. Structure-activity relationships. Biochim. Biophys. Acta, 1991, 1073, 33-42.
42. Hu, L.Y.; Abeles, R.H. Inhibition of cathepsin B and papain by peptidyl alpha-keto esters, alpha-keto amides, alpha-diketones, and alpha-keto acids. Arch. Biochem. Biophys., 1990, 281, 271-274.
43. Li, Z.; Patil, G.S.; Golubski, Z.E.; Hori, H.; Tehrani, K.; Foreman, J.E.; Eveleth, D.D.; Bartus, R.T.; Powers, J.C. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem., 1993, 36, 3472-3480.
44. Hanzlik, R.P.; Zygmunt, J.; Moon, J.B. Reversible covalent binding of peptide nitriles to papain. Biochim. Biophys. Acta, 1990, 1035,62-70.
45. Rasnick, D. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal. Biochem., 1985, 149, 461-465.
46. Gour-Salin, B.J.; Lachance, P.; Magny, M.C.; Plouffe, C.; Menard, R.; Storer, A.C. E64 [trans-epoxysuccinyl-L-leucylamido-(4- guanidino)butane] analogues as inhibitors of cysteine proteinases: investigation of S2 subsite interactions. Biochem. J., 1994, 299 (Pt2), 389-392.
47. Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Bromme, D. Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors. J. Med. Chem., 1995, 38, 3193-3196.
48. Rosenthal, P.J.; Wollish, W.S.; Palmer, J.T.; Rasnick, D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest., 1991, 88, 1467-1472.
49. Rosenthal, P.J.; Lee, G.K.; Smith, R.E. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest., 1993, 91, 1052-1056.
50. Rosenthal, P.J.; Olson, J.E.; Lee, G.K.; Palmer, J.T.; Klaus, J.L.; Rasnick, D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother., 1996, 40,1600-1603. (Pubitemid 26227342)
51. Schirmeister, T.; Klockow, A. Cysteine protease inhibitors containing small rings. Mini-Rev. Med. Chem., 2003, 3, 585-596.
52. Rosenthal, P.J.; McKerrow, J.H.; Aikawa, M.; Nagasawa, H.; Leech, J.H. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Invest., 1988, 82, 1560-1566.
53. Wickham, M.E.; Culvenor, J.G.; Cowman, A.F. Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte. J. Biol. Chem., 2003, 278, 37658-37663.
54. Olson, J.E.; Lee, G.K.; Semenov, A.; Rosenthal, P.J. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem., 1999, 7, 633-638.
55. Shenai, B.R.; Lee, B.J.; Alvarez-Hernandez, A.; Chong, P.Y.; Emal, C.D.; Neitz, R.J.; Roush, W.R.; Rosenthal, P.J. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother., 2003, 47, 154-160.
56. Valente, C.; Guedes, R.C.; Moreira, R.; Iley, J.; Gut, J.; Rosenthal, P.J. Dipeptide vinyl sultams: synthesis via the Wittig-Horner reaction and activity against papain, falcipain-2 and Plasmodium falciparum. Bioorg. Med. Chem. Lett., 2006, 16, 4115-4119.
57. Lee, B.J.; Singh, A.; Chiang, P.; Kemp, S.J.; Goldman, E.A.; Weinhouse, M.I.; Vlasuk, G.P.; Rosenthal, P.J. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother., 2003, 47, 3810-3814.
58. Chipeleme, A.; Gut, J.; Rosenthal, P.J.; Chibale, K. Synthesis and biological evaluation of phenolic Mannich bases of benzaldehyde and (thio)semicarbazone derivatives against the cysteine protease falcipain-2 and a chloroquine resistant strain of Plasmodium falciparum. Bioorg. Med. Chem., 2007, 15, 273-282.
59. Martichonok, V.; Plouffe, C.; Storer, A.C.; Menard, R.; Jones, J.B. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4- guanidinobutane (E-64) as inhibitors of cysteine proteases. J. Med. Chem., 1995, 38, 3078-3085.
60. Schulz, F.; Gelhaus, C.; Degel, B.; Vicik, R.; Heppner, S.; Breuning, A.; Leippe, M.; Gut, J.; Rosenthal, P.J.; Schirmeister, T. Screening of protease inhibitors as antiplasmodial agents. Part I: Aziridines and epoxides. Chem. Med. Chem., 2007, 2, 1214-1224.
61. Capela, R.; Oliveira, R.; Goncalves, L.M.; Domingos, A.; Gut, J.; Rosenthal, P.J.; Lopes, F.; Moreira, R. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg. Med. Chem. Lett., 2009, 19, 3229-3232.
62. Goud, P.M.; Sheri, A.; Desai, P.V.; Watkins, E.B.; Tekwani, B.; Sabnis, Y.; Gut, J.; Rosenthal, P.J.; Avery, M.A. Design, synthesis and evaluation of trisubstituted thiazoles targeting Plasmodium falciparum cysteine proteases. Med. Chem. Res., 2005, 14, 74-105.
63. Verissimo, E.; Berry, N.; Gibbons, P.; Cristiano, M.L.; Rosenthal, P.J.; Gut, J.; Ward, S.A.; O'Neill, P.M. Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4210-4214.
64. Micale, N.; Kozikowski, A.P.; Ettari, R.; Grasso, S.; Zappala, M.; Jeong, J.J.; Kumar, A.; Hanspal, M.; Chishti, A.H. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J. Med. Chem., 2006, 49, 3064-3067. (Pubitemid 43830505)
65. Ettari, R.; Nizi, E.; Di Francesco, M.E.; Micale, N.; Grasso, S.; Zappala, M.; Vicik, R.; Schirmeister, T. Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors. Chem. Med. Chem., 2008, 3, 1030-1033.
66. Ring, C.S.; Sun, E.; McKerrow, J.H.; Lee, G.K.; Rosenthal, P.J.; Kuntz, I.D.; Cohen, F.E. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. USA, 1993, 90, 3583-3587.
67. Li, R.; Chen, X.; Gong, B.; Dominguez, J.N.; Davidson, E.; Kurzban, G.; Miller, R.E.; Nuzum, E.O.; Rosenthal, P.J. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem., 1995, 38, 5031-5037. (Pubitemid 26012258)
68. Desai, P.V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. the chembridge database. J. Med. Chem., 2004, 47, 6609-6615. (Pubitemid 39657322)
69. Desai, P.V.; Patny, A.; Gut, J.; Rosenthal, P.J.; Tekwani, B.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. the available chemical directory. J. Med. Chem., 2006, 49, 1576-1584. (Pubitemid 43376503)
70. Li, H.; Huang, J.; Chen, L.; Liu, X.; Chen, T.; Zhu, J.; Lu, W.; Shen, X.; Li, J.; Hilgenfeld, R.; Jiang, H. Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. J. Med. Chem., ACS ASAP.
71. Zheng, S.; Luo, X.; Chen, G.; Zhu, W.; Shen, J.; Chen, K.; Jiang, H. A new rapid and effective chemistry space filter in recognizing a druglike database. J. Chem. Inf. Model., 2005, 45, 856-862.
72. Zhu, J.; Chen, T.; Liu, J.; Ma, R.; Lu, W.; Huang, J.; Li, H.; Li, J.; Jiang, H. 2-(3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) acetamides as a new class of falcipain-2 Inhibitors. 3. Design, synthesis and biological evaluation. Molecules, 2009, 14, 785-797.
73. Zhu, J.; Chen, T.; Chen, L.; Lu, W.; Che, P.; Huang, J.; Li, H.; Li, J.; Jiang, H. 2-amido-3-(1H-indol-3-yl)-N-substitued-propanamides as a new class of falcipain-2 inhibitors. 1. Design, synthesis, biological evaluation and binding model studies. Molecules, 2009,14, 494-508.
74. Desai, P.V.; Patny, A.; Gut, J.; Rosenthal, P.J.; Tekwani, B.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. the available chemical directory. J. Med. Chem., 2006, 49, 1576-1584. (Pubitemid 43376503)
75. Chen, M.; Theander, T.G.; Christensen, S.B.; Hviid, L.; Zhai, L.; Kharazmi, A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob. Agents Chemother., 1994, 38, 1470-1475.
76. Dominguez, J.N.; Charris, J.E.; Lobo, G.; Gamboa de Dominguez, N.; Moreno, M.M.; Riggione, F.; Sanchez, E.; Olson, J.; Rosenthal, P.J. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem., 2001, 36, 555-560. (Pubitemid 32781719)
77. Liu, M.; Wilairat, P.; Go, M.L. Antimalarial alkoxylated and hydroxylated chalcones [corrected]: structure-activity relationship analysis. J. Med. Chem., 2001, 44, 4443-4452.
78. Dominguez, J.N.; Leon, C.; Rodrigues, J.; Gamboa de Dominguez, N.; Gut, J.; Rosenthal, P.J. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J. Med. Chem., 2005, 48, 3654-3658. (Pubitemid 40664115)
79. Shuttleworth, S.J.; Nasturica, D.; Gervais, C.; Siddiqui, M.A.; Rando, R.F.; Lee, N. Parallel synthesis of isatin-based serine protease inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 2501-2504.
80. Webber, S.E.; Tikhe, J.; Worland, S.T.; Fuhrman, S.A.; Hendrickson, T.F.; Matthews, D.A.; Love, R.A.; Patick, A.K.; Meador, J.W.; Ferre, R.A.; Brown, E.L.; DeLisle, D.M.; Ford, C.E.; Binford, S.L. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J. Med. Chem., 1996, 39, 5072-5082. (Pubitemid 27008954)
81. Chiyanzu, I.; Hansell, E.; Gut, J.; Rosenthal, P.J.; McKerrow, J.H.; Chibale, K. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg. Med. Chem. Lett., 2003, 13, 3527-3530.
82. Fujii, N.; Mallari, J.P.; Hansell, E.J.; Mackey, Z.; Doyle, P.; Zhou, Y.M.; Gut, J.; Rosenthal, P.J.; McKerrow, J.H.; Guy, R.K. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg. Med. Chem. Lett., 2005, 15, 121-123. (Pubitemid 39575795)
83. Lee, N.; Hui, D.; Wu, A.; Chan, P.; Cameron, P.; Joynt, G.M.; Ahuja, A.; Yung, M.Y.; Leung, C.B.; To, K.F.; Lui, S.F.; Szeto, C.C.; Chung, S.; Sung, J.J. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med., 2003, 348,1986-1994. (Pubitemid 36569987)
84. Poutanen, S.M.; Low, D.E.; Henry, B.; Finkelstein, S.; Rose, D.; Green, K.; Tellier, R.; Draker, R.; Adachi, D.; Ayers, M.; Chan, A.K.; Skowronski, D.M.; Salit, I.; Simor, A.E.; Slutsky, A.S.; Doyle, P.W.; Krajden, M.; Petric, M.; Brunham, R.C.; McGeer, A.J. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med., 2003, 348, 1995-2005. (Pubitemid 36569988)
85. Tsang, K.W.; Ho, P.L.; Ooi, G.C.; Yee, W.K.; Wang, T.; Chan-Yeung, M.; Lam, W.K.; Seto, W.H.; Yam, L.Y.; Cheung, T.M.; Wong, P.C.; Lam, B.; Ip, M.S.; Chan, J.; Yuen, K.Y.; Lai, K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med., 2003, 348, 1977-1985. (Pubitemid 36569986)
86. Global Alert and Response (GAR), http://www.who.int/csr/sars/country/ table2004-04-21/en/index.html [Access date: August8, 2009].
87. Kuiken, T.; Fouchier, R.A.M.; Schutten, M.; Rimmelzwaan, G.F.; van Amerongen, G.; van Riel, D.; Laman, J.D.; de Jong, T.; van Doornum, G.; Lim, W.; Ling, A.E.; Chan, P.K.S.; Tam, J.S.; Zambon, M.C.; Gopal, R.; Drosten, C.; van der Werf, S.; Escriou, N.; Manuguerra, J.-C.; Stohr, K.; Peiris, J.S.M.; Osterhaus, A.D.M.E. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, 2003, 362, 263-270. (Pubitemid 36936836)
88. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W.; Rollin, P.E.; Dowell, S.F.; Ling, A.-E.; Humphrey, C.D.; Shieh, W.-J.; Guarner, J.; Paddock, C.D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J.-Y.; Cox, N.; Hughes, J.M.; LeDuc, J.W.; Bellini, W.J.; Anderson, L.J.; Cannon, A.D.L.; Curtis, M.; Farrar, B.; Morgan, L.; Pezzanite, L.; Sanchez, A.J.; Slaughter, K.A.; Stevens, T.L.; Stockton, P.C.; Wagoner, K.D.; Sanchez, A.; Nichol, S.; Vincent, M.; Osborne, J.; Honig, J.; Brickson, B.R.; Holloway, B.; McCaustland, K.; Lingappa, J.; Lowe, L.; Scott, S.; Lu, X.; Villamarzo, Y.; Cook, B.; Chen, Q.; Birge, C.; Shu, B.; Pallansch, M.; Tatti, K.M.; Morken, T.; Smith, C.; Greer, P.; White, E.; McGlothen, T.; Bhatnagar, J.; Patel, M.; Bartlett, J.; Montague, J.; Lee, W.; Packard, M.; Thompson, H.A.; Moen, A.; Fukuda, K.; Uyeki, T.; Harper, S.; Klimov, A.; Lindstrom, S.; Benson, R.; Carlone, G.; Facklam, R.; Fields, P.; Levett, P.; Mayer, L.; Talkington, D.; Thacker, W.L.; Tondella, M.L.C.; Whitney, C.; Robertson, B.; Warnock, D.; Brooks, T.; Schrag, S.; Rosenstein, N.; Arthur, R.; Ganem, D.; Poutanen, S.M.; Chen, T.J.; Hsiao, C.H.; Wai-Fu, N.G.; Ho, M.; Keung, T.K.; Nghiem, K.H.; Nguyen, H.K.L.; Le, M.Q.; Nguyen, H.H.T.; Hoang, L.T.; Vu, T.H.; Vu, H.Q.; Chunsuttiwat, S. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med., 2003, 348, 1953-1966. (Pubitemid 36569984)
89. Drosten, C.; Preiser, W.; Gunther, S.; Schmitz, H.; Doerr, H.W. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol. Med., 2003, 9, 325-327. (Pubitemid 37040026)
90. Thiel, V.; Ivanov, K.A.; Putics, A.; Hertzig, T.; Schelle, B.; Bayer, S.; Weissbrich, B.; Snijder, E.J.; Rabenau, H.; Doerr, H.W.; Gorbalenya, A.E.; Ziebuhr, J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol., 2003, 84,2305-2315. (Pubitemid 37063118)
91. Hsu, M.-F.; Kuo, C.-J.; Chang, K.-T.; Chang, H.-C.; Chou, C.-C.; Ko, T.-P.; Shr, H.-L.; Chang, G.-G.; Wang, A.H.J.; Liang, P.-H. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem., 2005, 280, 31257-31266.
92. Ziebuhr, J.; Snijder, E.J.; Gorbalenya, A.E. Virus-encoded proteinases and proteolytic processing in the nidovirales. J. Gen. Virol., 2000, 81, 853-879.
93. Ziebuhr, J.; Heusipp, G.; Siddell, S.G. Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase. J. Virol., 1997, 71, 3992-3997. (Pubitemid 27172414)
94. Xiong, B.; Gui, C.-S.; Xu, X.-Y.; Luo, C.; Chen, J.; Luo, H.-B.; Chen, L.-L.; Li, G.-W.; Sun, T.; Yu, C.-Y.; Yue, L.-D.; Duan, W.-H.; Shen, J.-K.; Qin, L.; Shi, T.-L.; Li, Y.-X.; Chen, K.-X.; Luo, X.-M.; Shen, X.; Shen, J.-H.; Jiang, H.-L. A 3D model of SARS-CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin., 2003, 24, 497-504.
95. Bacha, U.; Barrila, J.; Gabelli, S.B.; Kiso, Y.; Mario Amzel, L.; Freire, E. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem. Biol. Drug Des., 2008, 72, 34-49.
96. Ghosh, A.K.; Xi, K.; Ratia, K.; Santarsiero, B.D.; Fu, W.; Harcourt, B.H.; Rota, P.A.; Baker, S.C.; Johnson, M.E.; Mesecar, A.D. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem., 2005, 48, 6767-6771. (Pubitemid 41533095)
97. Lee, T.W.; Cherney, M.M.; Liu, J.; James, K.E.; Powers, J.C.; Eltis, L.D.; James, M.N. Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase. J. Mol. Biol., 2007, 366, 916-932.
98. Tan, J.; Verschueren, K.H.G.; Anand, K.; Shen, J.; Yang, M.; Xu, Y.; Rao, Z.; Bigalke, J.; Heisen, B.; Mesters, J.R.; Chen, K.; Shen, X.; Jiang, H.; Hilgenfeld, R. pH-dependent Conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple x-ray structure analyses. J. Mol. Biol., 2005, 354, 25-40.
99. Verschueren, K.H.; Pumpor, K.; Anemuller, S.; Chen, S.; Mesters, J.R.; Hilgenfeld, R. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem. Biol., 2008, 15, 597-606.
100. Xu, T.; Ooi, A.; Lee, H.C.; Wilmouth, R.; Liu, D.X.; Lescar, J. Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer. Acta Crystallogr. Sect F Struct. Biol. Cryst. Commun., 2005, 61, 964-966. (Pubitemid 44210728)
101. Xue, X.; Yu, H.; Yang, H.; Xue, F.; Wu, Z.; Shen, W.; Li, J.; Zhou, Z.; Ding, Y.; Zhao, Q.; Zhang, X.C.; Liao, M.; Bartlam, M.; Rao, Z. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol., 2008, 82,2515-2527.
102. Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; Hilgenfeld, R.; Yuen, K.Y.; Wong, L.; Gao, G.; Chen, S.; Chen, Z.; Ma, D.; Bartlam, M.; Rao, Z. Design of wide-spectrum inhibitors targeting Coronavirus main proteases. PLoS Biol., 2005, 3, 1742-1752.
103. Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G.F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA, 2003, 100, 13190-13195. (Pubitemid 37444717)
104. Yin, J.; Niu, C.; Cherney, M.M.; Zhang, J.; Huitema, C.; Eltis, L.D.; Vederas, J.C.; James, M.N. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARSCoV 3C-like peptidase. J. Mol. Biol., 2007, 371, 1060-1074.
105. Anand, K.; Palm, G.J.; Mesters, J.R.; Siddell, S.G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha -helical domain. EMBO J., 2002, 21, 3213-3224. (Pubitemid 34760554)
106. Chen, S.; Luo, H.; Chen, L.; Chen, J.; Shen, J.; Zhu, W.; Chen, K.; Shen, X.; Jiang, H. An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development. Curr. Pharm. Des., 2006, 12, 4539-4553.
107. Shi, J.; Wei, Z.; Song, J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J. Biol. Chem., 2004, 279, 24765-24773. (Pubitemid 38725344)
108. Kuang, W.F.; Chow, L.P.; Wu, M.H.; Hwang, L.H. Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays. Biochem. Biophys. Res. Commun., 2005, 331, 1554-1559. (Pubitemid 40692532)
109. Chen, S.; Chen, L.; Tan, J.; Chen, J.; Du, L.; Sun, T.; Shen, J.; Chen, K.; Jiang, H.; Shen, X. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization: biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. J. Biol. Chem., 2005, 280, 164-173. (Pubitemid 40164977)
110. Hsu, W.-C.; Chang, H.-C.; Chou, C.-Y.; Tsai, P.-J.; Lin, P.-I.; Chang, G.-G. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J. Biol. Chem., 2005, 280, 22741-22748.
111. Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; Hilgenfeld, R.; Yuen, K.Y.; Wong, L.; Gao, G.; Chen, S.; Chen, Z.; Ma, D.; Bartlam, M.; Rao, Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol., 2005, 3, e324.
112. Fan, K.; Wei, P.; Feng, Q.; Chen, S.; Huang, C.; Ma, L.; Lai, B.; Pei, J.; Liu, Y.; Chen, J.; Lai, L. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem., 2004, 279, 1637-1642. (Pubitemid 38084429)
113. Goetz, D.H.; Choe, Y.; Hansell, E.; Chen, Y.T.; McDowell, M.; Jonsson, C.B.; Roush, W.R.; McKerrow, J.; Craik, C.S. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry, 2007, 46, 8744-8752.
114. Sirois, S.; Wei, D.Q.; Du, Q.; Chou, K.C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem. Inf. Comput. Sci., 2004, 44, 1111-1122.
115. Xue, X.; Yang, H.; Shen, W.; Zhao, Q.; Li, J.; Yang, K.; Chen, C.; Jin, Y.; Bartlam, M.; Rao, Z. Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol., 2007, 366,965-975. (Pubitemid 46175874)
116. Dragovich, P.S.; Prins, T.J.; Zhou, R.; Webber, S.E.; Marakovits, J.T.; Fuhrman, S.A.; Patick, A.K.; Matthews, D.A.; Lee, C.A.; Ford, C.E.; Burke, B.J.; Rejto, P.A.; Hendrickson, T.F.; Tuntland, T.; Brown, E.L.; Meador, J.W., 3rd; Ferre, R.A.; Harr, J.E.; Kosa, M.B.; Worland, S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem., 1999, 42, 1213-1224.
117. Matthews, D.A.; Dragovich, P.S.; Webber, S.E.; Fuhrman, S.A.; Patick, A.K.; Zalman, L.S.; Hendrickson, T.F.; Love, R.A.; Prins, T.J.; Marakovits, J.T.; Zhou, R.; Tikhe, J.; Ford, C.E.; Meador, J.W.; Ferre, R.A.; Brown, E.L.; Binford, S.L.; Brothers, M.A.; Delisle, D.M.; Worland, S.T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA, 1999, 96, 11000-11007.
118. Patick, A.K.; Binford, S.L.; Brothers, M.A.; Jackson, R.L.; Ford, C.E.; Diem, M.D.; Maldonado, F.; Dragovich, P.S.; Zhou, R.; Prins, T.J.; Fuhrman, S.A.; Meador, J.W.; Zalman, L.S.; Matthews, D.A.; Worland, S.T. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother., 1999, 43, 2444-2450.
119. Ghosh, A.K.; Xi, K.; Ratia, K.; Santarsiero, B.D.; Fu, W.; Harcourt, B.H.; Rota, P.A.; Baker, S.C.; Johnson, M.E.; Mesecar, A.D. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J. Med. Chem., 2005, 48, 6767-6771. (Pubitemid 41533095)
120. Shie, J.-J.; Fang, J.-M.; Kuo, T.-H.; Kuo, C.-J.; Liang, P.-H.; Huang, H.-J.; Wu, Y.-T.; Jan, J.-T.; Cheng, Y.-S.E.; Wong, C.-H. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta -unsaturated esters. Bioorg. Med. Chem., 2005, 13, 5240-5252. (Pubitemid 41039985)
121. Wu, C.-Y.; Jan, J.-T.; Ma, S.-H.; Kuo, C.-J.; Juan, H.-F.; Cheng, Y.-S.E.; Hsu, H.-H.; Huang, H.-C.; Wu, D.; Brik, A.; Liang, F.-S.; Liu, R.-S.; Fang, J.-M.; Chen, S.-T.; Liang, P.-H.; Wong, C.-H. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA, 2004, 101, 10012-10017. (Pubitemid 38898719)
122. Wu, C.J.; Jan, J.T.; Chen, C.M.; Hsieh, H.P.; Hwang, D.R.; Liu, H.W.; Liu, C.Y.; Huang, H.W.; Chen, S.C.; Hong, C.F.; Lin, R.K.; Chao, Y.S.; Hsu, J.T. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother., 2004, 48, 2693-2696. (Pubitemid 38823443)
123. Shie, J.-J.; Fang, J.-M.; Kuo, C.-J.; Kuo, T.-H.; Liang, P.-H.; Huang, H.-J.; Yang, W.-B.; Lin, C.-H.; Chen, J.-L.; Wu, Y.-T.; Wong, C.-H. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J. Med. Chem., 2005, 48, 4469-4473. (Pubitemid 40884948)
124. Chou, K.-C.; Wei, D.-Q.; Zhong, W.-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun., 2003, 308, 148-151.
125. Chou, K.C.; Wei, D.Q.; Du, Q.S.; Sirois, S.; Zhong, W.Z. Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13, 3263-3270.
126. Du, Q.-S.; Wang, S.-Q.; Zhu, Y.; Wei, D.-Q.; Guo, H.; Sirois, S.; Chou, K.-C. Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide. Peptides (N. Y., NY, U. S.). 2004, 25, 1857-1864.
127. Jain, R.P.; Vederas, J.C. Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase. Bioorg. Med. Chem. Lett., 2004, 14, 3655-3658.
128. Ramtohul, Y.K.; James, M.N.; Vederas, J.C. Synthesis and evaluation of keto-glutamine analogues as inhibitors of hepatitis A virus 3C proteinase. J. Org. Chem., 2002, 67, 3169-3178. (Pubitemid 34517693)
129. Jain, R.P.; Pettersson, H.I.; Zhang, J.; Aull, K.D.; Fortin, P.D.; Huitema, C.; Eltis, L.D.; Parrish, J.C.; James, M.N.G.; Wishart, D.S.; Vederas, J.C. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J. Med. Chem., 2004, 47, 6113-6116.
130. Bacha, U.; Barrila, J.; Velazquez-Campoy, A.; Leavitt, S.A.; Freire, E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry, 2004, 43, 4906-4912. (Pubitemid 38544444)
131. Zhang, H.Z.; Zhang, H.; Kemnitzer, W.; Tseng, B.; Cinatl, J., Jr.; Michaelis, M.; Doerr, H.W.; Cai, S.X. Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J. Med. Chem., 2006, 49, 1198-1201.
132. Kong, J.S.; Venkatraman, S.; Furness, K.; Nimkar, S.; Shepherd, T.A.; Wang, Q.M.; Aube, J.; Hanzlik, R.P. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J. Med. Chem., 1998, 41, 2579-2587.
133. Morris, T.S.; Frormann, S.; Shechosky, S.; Lowe, C.; Lall, M.S.; Gauss-Muller, V.; Purcell, R.H.; Emerson, S.U.; Vederas, J.C.; Malcolm, B.A. In vitro and ex vivo inhibition of hepatitis A virus 3C proteinase by a peptidyl monofluoromethyl ketone. Bioorg. Med. Chem., 1997, 5, 797-807.
134. Gelb, M.H.; Svaren, J.P.; Abeles, R.H. Fluoro ketone inhibitors of hydrolytic enzymes. Biochemistry. 1985, 24, 1813-1817.
135. Patel, D.V.; Rielly-Gauvin, K.; Ryono, D.E.; Free, C.A.; Smith, S.A.; Petrillo, E.W., Jr. Activated ketone based inhibitors of human renin. J. Med. Chem., 1993, 36, 2431-2447.
136. Sydnes, M.O.; Hayashi, Y.; Sharma, V.K.; Hamada, T.; Bacha, U.; Barrila, J.; Freire, E.; Kiso, Y. Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors. Tetrahedron. 2006, 62, 8601-8609. (Pubitemid 44107390)
137. Regnier, T.; Sarma, D.; Hidaka, K.; Bacha, U.; Freire, E.; Hayashi, Y.; Kiso, Y. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 2722-2727.
138. Shao, Y.M.; Yang, W.B.; Kuo, T.H.; Tsai, K.C.; Lin, C.H.; Yang, A.S.; Liang, P.H.; Wong, C.H. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg. Med. Chem., 2008, 16, 4652-4660.
139. James, K.E.; Gotz, M.G.; Caffrey, C.R.; Hansell, E.; Carter, W.; Barrett, A.J.; McKerrow, J.H.; Powers, J.C. Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol. Chem., 2003, 384, 1613-1618.
140. James, K.E.; Asgian, J.L.; Li, Z.Z.; Ekici, O.D.; Rubin, J.R.; Mikolajczyk, J.; Salvesen, G.S.; Powers, J.C. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J. Med. Chem., 2004, 47, 1553-1574. (Pubitemid 38327479)
141. Lee, T.-W.; Cherney, M.M.; Huitema, C.; Liu, J.; James, K.E.; Powers, J.C.; Eltis, L.D.; James, M.N.G. Crystal structures of the main peptidase from the SARS Coronavirus inhibited by a substrate-like Aza-peptide epoxide. J. Mol. Biol., 2005, 353, 1137-1151.
142. Barabas, E.; Szell, E.; Bajusz, S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul. Fibrinol., 1993, 4, 243-248. (Pubitemid 23103800)
143. McConnell, R.M.; York, J.L.; Frizzell, D.; Ezell, C. Inhibition studies of some serine and thiol proteinases by new leupeptin analogues. J. Med. Chem., 1993, 36, 1084-1089. (Pubitemid 23143621)
144. Fehrentz, J.A.; Heitz, A.; Castro, B.; Cazaubon, C.; Nisato, D. Aldehydic peptides inhibiting renin. FEBS Lett., 1984, 167, 273-276.
145. Sarubbi, E.; Seneci, P.F.; Angelastro, M.R.; Peet, N.P.; Denaro, M.; Islam, K. Peptide aldehydes as inhibitors of HIV protease. FEBS Lett., 1993, 319, 253-256. (Pubitemid 23080223)
146. Thornberry, N.A.; Bull, H.G.; Calaycay, J.R.; Chapman, K.T.; Howard, A.D.; Kostura, M.J.; Miller, D.K.; Molineaux, S.M.; Weidner, J.R.; Aunins, J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992, 356, 768-774.
147. Graybill, T.L.; Dolle, R.E.; Helaszek, C.T.; Miller, R.E.; Ator, M.A. Preparation and evaluation of peptidic aspartyl hemiacetals as reversible inhibitors of interleukin-1 beta converting enzyme (ICE). Int. J. Pept. Protein Res., 1994, 44, 173-182.
148. Al-Gharabli, S.I.; Shah, S.T.A.; Weik, S.; Schmidt, M.F.; Mesters, J.R.; Kuhn, D.; Klebe, G.; Hilgenfeld, R.; Rademann, J. An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chem. Bio. Chem., 2006, 7,1048-1055. (Pubitemid 44049439)
149. Liu, Z.; Huang, C.; Fan, K.; Wei, P.; Chen, H.; Liu, S.; Pei, J.; Shi, L.; Li, B.; Yang, K.; Liu, Y.; Lai, L. Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J. Chem. Inf. Comput. Sci., 2005, 45, 10-17.
150. Chen, L.; Gui, C.; Luo, X.; Yang, Q.; Guenther, S.; Scandella, E.; Drosten, C.; Bai, D.; He, X.; Ludewig, B.; Chen, J.; Luo, H.; Yang, Y.; Yang, Y.; Zou, J.; Thiel, V.; Chen, K.; Shen, J.; Shen, X.; Jiang, H. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol., 2005, 79, 7095-7103. (Pubitemid 40677341)
151. Clark, R.D.; Strizhev, A.; Leonard, J.M.; Blake, J.F.; Matthew, J.B. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model., 2002, 20, 281-295.
152. Lu, I.L.; Mahindroo, N.; Liang, P.-H.; Peng, Y.-H.; Kuo, C.-J.; Tsai, K.-C.; Hsieh, H.-P.; Chao, Y.-S.; Wu, S.-Y. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J. Med. Chem., 2006, 49, 5154-5161.
153. Dooley, A.J.; Shindo, N.; Taggart, B.; Park, J.-G.; Pang, Y.-P. From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus. Bioorg. Med. Chem. Lett., 2006, 16, 830-833.
154. Tsai, K.C.; Chen, S.Y.; Liang, P.H.; Lu, I.L.; Mahindroo, N.; Hsieh, H.P.; Chao, Y.S.; Liu, L.; Liu, D.; Lien, W.; Lin, T.H.; Wu, S.Y. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem., 2006, 49, 3485-3495.
155. Yang, H.; Bartlam, M.; Rao, Z. Drug design targeting the main protease, the achilles' heel of coronaviruses. Curr. Pharm. Des., 2006, 12, 4573-4590.
156. Kao, R.Y.; Tsui, W.H.W.; Lee, T.S.W.; Tanner, J.A.; Watt, R.M.; Huang, J.-D.; Hu, L.; Chen, G.; Chen, Z.; Zhang, L.; He, T.; Chan, K.-H.; Tse, H.; To, A.P.C.; Ng, L.W.Y.; Wong, B.C.W.; Tsoi, H.-W.; Yang, D.; Ho, D.D.; Yuen, K.-Y. Identification of novel smallmolecule inhibitors of severe acute respiratory syndromeassociated Coronavirus by chemical genetics. Chem. Biol., 2004, 11, 1293-1299.
157. Blanchard, J.E.; Elowe, N.H.; Huitema, C.; Fortin, P.D.; Cechetto, J.D.; Eltis, L.D.; Brown, E.D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol., 2004, 11, 1445-1453. (Pubitemid 39365165)
158. Kuo, C.J.; Liu, H.G.; Lo, Y.K.; Seong, C.M.; Lee, K.I.; Jung, Y.S.; Liang, P.H. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett., 2009, 583, 549-555.
159. Hsu, J.T.A.; Kuo, C.-J.; Hsieh, H.-P.; Wang, Y.-C.; Huang, K.-K.; Lin, C.P.C.; Huang, P.-F.; Chen, X.; Liang, P.-H. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett., 2004, 574, 116-120.
160. Liu, Y.-C.; Huang, V.; Chao, T.-C.; Hsiao, C.-D.; Lin, A.; Chang, M.-F.; Chow, L.-P. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. Biochem. Biophys. Res. Commun., 2005, 333, 194-199.
161. Chen, C.N.; Lin, C.P.; Huang, K.K.; Chen, W.C.; Hsieh, H.P.; Liang, P.H.; Hsu, J.T. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3). Evid Based Compl. Alt. Med., 2005, 2, 209-215.
162. Kaeppler, U.; Stiefl, N.; Schiller, M.; Vicik, R.; Breuning, A.; Schmitz, W.; Rupprecht, D.; Schmuck, C.; Baumann, K.; Ziebuhr, J.; Schirmeister, T. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. J. Med. Chem., 2005, 48, 6832-6842. (Pubitemid 41533105)
163. Lin, C.-W.; Tsai, F.-J.; Tsai, C.-H.; Lai, C.-C.; Wan, L.; Ho, T.-Y.; Hsieh, C.-C.; Chao, P.-D.L. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res., 2005, 68, 36-42.
164. Jenwitheesuk, E.; Samudrala, R. Identifying inhibitors of the SARS coronavirus proteinase. Bioorg. Med. Chem. Lett., 2003, 13, 3989-3992. (Pubitemid 37338433)
165. Plewczynski, D.; Hoffmann, M.; von Grotthuss, M.; Ginalski, K.; Rychewski, L. In silico prediction of SARS protease inhibitors by virtual high throughput screening. Chem. Biol. Drug Des., 2007, 69, 269-279. (Pubitemid 46663179)
166. Zhang, X.W.; Yap, Y.L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg. Med. Chem., 2004, 12, 2517-2521.
167. Savarino, A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J. Clin. Virol., 2005, 34, 170-178. (Pubitemid 41427312)
168. Zhang, X.W.; Yap, Y.L.; Altmeyer, R.M. Generation of predictive pharmacophore model for SARS-coronavirus main proteinase. Eur. J. Med. Chem., 2005, 40, 57-62.
169. Schmidt, M.F.; Isidro-Llobet, A.; Lisurek, M.; El-Dahshan, A.; Tan, J.; Hilgenfeld, R.; Rademann, J. Sensitized detection of inhibitory fragments and iterative development of non-peptidic protease inhibitors by dynamic ligation screening. Angew. Chem. Int. Ed. Engl., 2008, 47, 3275-3278.
170. Noedl, H.; Se, Y.; Schaecher, K.; Smith, B.L.; Socheat, D.; Fukuda, M.M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med., 2008, 359, 2619-2620.